Amanda F. Cashen

8.7k total citations
121 papers, 2.9k citations indexed

About

Amanda F. Cashen is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Amanda F. Cashen has authored 121 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Pathology and Forensic Medicine, 55 papers in Oncology and 37 papers in Genetics. Recurrent topics in Amanda F. Cashen's work include Lymphoma Diagnosis and Treatment (65 papers), Chronic Lymphocytic Leukemia Research (35 papers) and CAR-T cell therapy research (24 papers). Amanda F. Cashen is often cited by papers focused on Lymphoma Diagnosis and Treatment (65 papers), Chronic Lymphocytic Leukemia Research (35 papers) and CAR-T cell therapy research (24 papers). Amanda F. Cashen collaborates with scholars based in United States, Canada and Italy. Amanda F. Cashen's co-authors include John F. DiPersio, Nancy L. Bartlett, Ravi Vij, Keith Stockerl‐Goldstein, Peter Westervelt, Geoffrey L. Uy, Todd A. Fehniger, Barry A. Siegel, Feng Gao and Camille N. Abboud and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Blood.

In The Last Decade

Amanda F. Cashen

116 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amanda F. Cashen United States	29	1.4k	1.0k	891	629	549	121	2.9k
Frank Hartmann Germany	25	954 0.7×	910 0.9×	514 0.6×	561 0.9×	319 0.6×	82	2.8k
Mathias Witzens‐Harig Germany	30	1.1k 0.8×	1.3k 1.2×	665 0.7×	540 0.9×	738 1.3×	136	2.8k
Timothy S. Fenske United States	27	1.2k 0.9×	1.7k 1.6×	543 0.6×	435 0.7×	624 1.1×	162	2.6k
Scott Ely United States	28	1.1k 0.8×	1.6k 1.6×	872 1.0×	1.3k 2.0×	737 1.3×	89	3.4k
Eva Giné Spain	32	2.0k 1.5×	1.4k 1.3×	461 0.5×	444 0.7×	1.4k 2.5×	107	3.0k
Loïc Ysebaert France	33	1.7k 1.2×	1.5k 1.4×	398 0.4×	804 1.3×	1.1k 2.0×	139	3.7k
Jeffrey Matous United States	29	2.3k 1.7×	1.8k 1.8×	1.2k 1.4×	1.0k 1.6×	1.6k 2.8×	128	4.2k
Rémy Gressin France	26	1.7k 1.3×	1.2k 1.2×	276 0.3×	379 0.6×	880 1.6×	109	2.5k
Monica Bocchia Italy	28	850 0.6×	1.0k 1.0×	1.3k 1.4×	560 0.9×	1.1k 1.9×	179	2.9k
Lapo Alinari United States	30	1.7k 1.2×	793 0.8×	189 0.2×	623 1.0×	491 0.9×	115	2.8k

Countries citing papers authored by Amanda F. Cashen

Since Specialization

Citations

This map shows the geographic impact of Amanda F. Cashen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda F. Cashen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda F. Cashen more than expected).

Fields of papers citing papers by Amanda F. Cashen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda F. Cashen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda F. Cashen. The network helps show where Amanda F. Cashen may publish in the future.

Co-authorship network of co-authors of Amanda F. Cashen

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda F. Cashen. A scholar is included among the top collaborators of Amanda F. Cashen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda F. Cashen. Amanda F. Cashen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desai, Pinkal, Sagar Lonial, Amanda F. Cashen, et al.. (2024). A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies. Clinical Cancer Research. 30(21). 4844–4855. 15 indexed citations

Ghobadi, Armin, Michael P. Rettig, Amanda F. Cashen, et al.. (2023). Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Blood Advances. 8(3). 513–522. 6 indexed citations

Rutella, Sergio, Amanda F. Cashen, John Muth, et al.. (2023). S129: ADOPTIVELY INFUSED MEMORY-LIKE (ML) NATURAL KILLER (NK) CELLS ELICIT ADAPTIVE IMMUNE RESPONSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML). HemaSphere. 7(S3). e4299744–e4299744. 1 indexed citations

Munshi, Pashna N., Yue Chen, Kwang Woo Ahn, et al.. (2022). Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplantation and Cellular Therapy. 28(8). 487.e1–487.e7. 11 indexed citations

Saba, Raya, et al.. (2022). Engraftment Syndrome in Patients with Relapsed Refractory Classical Hodgkin Lymphoma Who Received PD-1 Blockade Containing Salvage Therapy Followed By Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. 28(3). S406–S406. 1 indexed citations

Abboud, Ramzi, Feng Gao, Michael P. Rettig, et al.. (2022). A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(3). S298–S299. 1 indexed citations

Salter, Amber, Marcus P. Watkins, Daniel R. Ludwig, et al.. (2022). Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. Cancers. 14(12). 2932–2932. 5 indexed citations

Savani, Malvi, Kwang Woo Ahn, Yue Chen, et al.. (2022). Impact of conditioning regimen intensity on the outcomes of peripheral T‐cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T‐cell lymphoma patients undergoing allogeneic transplant. British Journal of Haematology. 197(2). 212–222. 12 indexed citations

Fong, Jerry J., Jacob R. Gardner, Jared Andrews, et al.. (2021). Determining subpopulation methylation profiles from bisulfite sequencing data of heterogeneous samples using DXM. Nucleic Acids Research. 49(16). e93–e93. 10 indexed citations

10.

Fakhri, Bita, Feng Gao, Richard F. Ambinder, et al.. (2021). Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. Leukemia & lymphoma. 62(10). 2408–2415. 1 indexed citations

11.

Ward, Jeffrey P., Melissa M. Berrien-Elliott, Felicia Gomez, et al.. (2021). Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood. 139(13). 1999–2010. 23 indexed citations

12.

Badar, Talha, Narendranath Epperla, Anikó Szabó, et al.. (2020). Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Advances. 4(1). 47–54. 13 indexed citations

13.

Mehta–Shah, Neha, Amanda F. Cashen, Anne Beaven, et al.. (2020). Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis. Blood. 130. 4597–4597. 7 indexed citations

14.

Foltz, Jennifer A., Melissa M. Berrien-Elliott, Carly C. Neal, et al.. (2019). Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT). Blood. 134(Supplement_1). 1954–1954. 16 indexed citations

15.

Shah, Nirav N., Anikó Szabó, Raya Saba, et al.. (2018). Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clinical Lymphoma Myeloma & Leukemia. 19(2). 95–102. 9 indexed citations

16.

Smith, Sonali M., Sonali M. Smith, Brandelyn N. Pitcher, et al.. (2017). Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. The Lancet Haematology. 4(4). e176–e182. 63 indexed citations

17.

Ali, Alaa M., Feng Gao, Geoffrey L. Uy, et al.. (2017). Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen. Cancer Medicine. 6(12). 2814–2821. 21 indexed citations

18.

Lee, Yi-Shan, Jingxia Liu, Ravi Vij, et al.. (2017). Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 23(12). 2199–2204. 7 indexed citations

19.

Krysiak, Kilannin, Felicia Gomez, Brian S. White, et al.. (2016). Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 129(4). 473–483. 110 indexed citations

20.

Fehniger, Todd A., Geoffrey L. Uy, Kathryn Trinkaus, et al.. (2010). A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 117(6). 1828–1833. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact